BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 23494602)

  • 1. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
    Brown JW; Coles AJ
    Drug Des Devel Ther; 2013; 7():131-8. PubMed ID: 23494602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
    ; Coles AJ; Compston DA; Selmaj KW; Lake SL; Moran S; Margolin DH; Norris K; Tandon PK
    N Engl J Med; 2008 Oct; 359(17):1786-801. PubMed ID: 18946064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
    Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Giovannoni G; Cohen JA; Coles AJ; Hartung HP; Havrdova E; Selmaj KW; Margolin DH; Lake SL; Kaup SM; Panzara MA; Compston DA;
    Neurology; 2016 Nov; 87(19):1985-1992. PubMed ID: 27733571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Skoromets A; Stolyarov I; Bass A; Sullivan H; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Neurology; 2012 Apr; 78(14):1069-78. PubMed ID: 22442431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab for multiple sclerosis.
    Riera R; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
    Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
    Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
    Graves J; Galetta SL; Palmer J; Margolin DH; Rizzo M; Bilbruck J; Balcer LJ
    Mult Scler; 2013 Sep; 19(10):1302-9. PubMed ID: 23459567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
    J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
    Hartung HP; Aktas O; Boyko AN
    Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
    Jones JL; Anderson JM; Phuah CL; Fox EJ; Selmaj K; Margolin D; Lake SL; Palmer J; Thompson SJ; Wilkins A; Webber DJ; Compston DA; Coles AJ
    Brain; 2010 Aug; 133(Pt 8):2232-47. PubMed ID: 20659956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of action and clinical studies with alemtuzumab.
    Jones JL; Coles AJ
    Exp Neurol; 2014 Dec; 262 Pt A():37-43. PubMed ID: 24792641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on alemtuzumab.
    Jones JL; Coles AJ
    Int MS J; 2009 Sep; 16(3):77-81. PubMed ID: 19878629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ALEMTUZUMAB: BENEFITS AND CHALLENGES OF A NEW THERAPY IN MULTIPLE SCLEROSIS].
    Illés Z; Sejbaek T; Csépány T
    Ideggyogy Sz; 2015 May; 68(5-6):155-64. PubMed ID: 26182606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis.
    Garnock-Jones KP
    Drugs; 2014 Mar; 74(4):489-504. PubMed ID: 24604792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Cuker A; Coles AJ; Sullivan H; Fox E; Goldberg M; Oyuela P; Purvis A; Beardsley DS; Margolin DH
    Blood; 2011 Dec; 118(24):6299-305. PubMed ID: 21960587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.